Cytokinetics Director Robert Harrington Receives 151 Shares via Equity Retainer Program

This Form 4 filing reports that Robert Arthur Harrington, a director of Cytokinetics Inc., received 151 shares of common stock on July 15, 2026, through the company's Equity in lieu of Cash Retainer Program. The shares were granted at a price of $82.62 per share and were fully vested at the time of grant. Following this transaction, Dr. Harrington's total holdings in Cytokinetics common stock increased to 21,932 shares. The filing indicates this was an acquisition (transaction code A) of non-derivative securities. The transaction was filed on July 16, 2026, with John Faurescu signing as attorney-in-fact for Dr. Harrington. This represents a routine equity compensation transaction for a board member under the company's established retainer program.